(P023) Dosimetric Evaluation of Accelerated Partial Breast Irradiation Utilizing the ViewRay Magnetic Resonance Image-Guided Radiation Therapy System

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

MRI-guided EBRT using the ViewRay system is a novel approach to deliver APBI. ViewRay APBI is noninvasive yet maintains a high degree of precision by using prefraction MR imaging, thus allowing a reduction in the PTV margin. The resultant decrease in the ipsilateral breast dose may reduce acute skin toxicity and improve cosmetic outcomes. Thus, the ViewRay system is an attractive alternative to existing APBI techniques.

Benjamin W. Fischer-Valuck, MD, Karl Sona, Sahaja Acharya, MD, Min Yang, Rojano Kashani, PhD, Imran Zoberi, MD, Maria Thomas, MD, PhD; Washington University

PURPOSE: External beam radiation therapy (EBRT) is a noninvasive alternative to deliver accelerated partial breast irradiation (APBI). However, due to the larger target volume, cosmetic outcomes after EBRT APBI may be inferior to more invasive techniques, such as brachytherapy. Utilizing the ViewRay magnetic resonance imaging (MRI)-guided radiation therapy system, MRI can be used for planning and daily positioning, as well as for precise targeting during treatment. This prefraction imaging allows for a reduction in the planning target volume (PTV) margin, which may improve acute skin toxicity and cosmetic outcomes compared with traditional EBRT methods.

MATERIALS AND METHODS: Ten patients with ductal carcinoma in situ (DCIS) or early-stage invasive breast cancer and negative axillary lymph nodes were treated with APBI using the ViewRay system. Prescription dose to the PTV was 38.5 Gy, delivered in 10 fractions, twice daily. The PTV for ViewRay treatment planning included a 1-cm margin around the lumpectomy cavity. Comparison three-dimensional conformal EBRT (3DCRT) plans for each patient were generated using the Pinnacle planning system and a 2-cm margin around the lumpectomy cavity. Dosimetric parameters for the PTV, ipsilateral breast, and other critical structures for each treatment plan were compared.

RESULTS: Using the ViewRay system to obtain MR imaging for setup prior to each fraction, we observed that the lumpectomy cavity could be precisely localized and aligned prior to each fraction. A decrease in the PTV margin using the ViewRay system resulted in a mean PTV volume of 85 cc compared with 177 cc for 3DCRT. The median PTV receiving 95% of the prescribed dose for both the ViewRay and 3DCRT plans was 100%. Mean volume of the ipsilateral breast receiving the prescription dose was 11.72% for ViewRay treatment plans compared with 21.56% for 3DCRT treatment plans (P < .04). Mean volume of the ipsilateral breast receiving 50% of the prescribed dose using the ViewRay treatment plan was 31.34% compared with 52.71% for the 3DCRT treatment plans (P < .02). Reductions in the mean volumes of the ipsilateral lung, heart, and contralateral breast with the ViewRay plans were also observed, although they were not statistically significant.

CONCLUSION: MRI-guided EBRT using the ViewRay system is a novel approach to deliver APBI. ViewRay APBI is noninvasive yet maintains a high degree of precision by using prefraction MR imaging, thus allowing a reduction in the PTV margin. The resultant decrease in the ipsilateral breast dose may reduce acute skin toxicity and improve cosmetic outcomes. Thus, the ViewRay system is an attractive alternative to existing APBI techniques.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content